Brain patch trial aims to sharpen thinking in schizophrenia
NCT ID NCT06502964
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a skin patch called ALTO-101 can improve cognitive function in people with schizophrenia who have thinking problems. About 82 participants will receive either the active patch or a placebo, then switch after a period. The main goal is to see changes in brain wave activity linked to cognition, along with safety and tolerability.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ALTO-101
What this could lead to
If successful, this could point toward a new treatment for cognitive problems in schizophrenia, potentially improving thinking and daily function.
What could go wrong
This is an early Phase 2 trial with only 82 people. It measures brain activity, not real-world thinking, so even positive results may not translate to meaningful benefits. Side effects are unknown.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COGNITIVE IMPAIRMENT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Site 5015
RECRUITINGTampa, Florida, 33629, United States
-
Site 5035
RECRUITINGWalnut Creek, California, 94596, United States
Contact
-
Site 5038
RECRUITINGGarden Grove, California, 92845, United States
Contact
-
Site 5056
RECRUITINGChicago, Illinois, 60640, United States
Contact
-
Site 5060
RECRUITINGHollywood, Florida, 33024, United States
Contact
-
Site 5062
RECRUITINGGaithersburg, Maryland, 20877, United States
Contact
-
Site 5063
RECRUITINGLos Angeles, California, 90015, United States
Contact
-
Site 5064
RECRUITINGSnellville, Georgia, 30078, United States
Contact
-
Site 5077
RECRUITINGNew York, New York, 10032, United States
Contact
-
Site 5106
RECRUITINGOrange, California, 92868, United States
Contact
-
Site 5108
RECRUITINGNew York, New York, 10027, United States
Contact
-
Site 5109
WITHDRAWNNew York, New York, 10035, United States
-
Site 5124
RECRUITINGBelmont, Massachusetts, 02478, United States
Contact
-
Site 5126
RECRUITINGWhite Plains, New York, 10605, United States
Contact